Document is current
Any future updates will be listed below
-
Authors
Kelemen, M.
Danesh, J.
Di Angelantonio, E.
Inouye, M. http://orcid.org/0000-0001-9413-6520
O’Sullivan, J.
Pennells, L. http://orcid.org/0000-0002-8594-3061
Roychowdhury, T.
Sweeting, M. J.
Wood, A. M. http://orcid.org/0000-0002-7937-304X
Harrison, S.
Kim, L. G. http://orcid.org/0000-0002-4552-3820
-
Funding
Funding for this research was provided by:
British Heart Foundation (RG/18/13/33946)
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 9 September 2024
First Online: 14 September 2024
Competing interests
: J.D. serves on scientific advisory boards for AstraZeneca, Novartis, and UK Biobank, and has received multiple grants from academic, charitable and industry sources outside of the submitted work. M.I. is a trustee of the Public Health Genomics (PHG) Foundation, a member of the Scientific Advisory Board of Open Targets, and has research collaborations with AstraZeneca, Nightingale Health and Pfizer which are unrelated to this study. M.J.S. reports full-time employment with AstraZeneca and AstraZeneca stock ownership. S.H. is an employee at Genomics PLC. The other authors declare no competing interests.
